157 related articles for article (PubMed ID: 15266173)
1. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
2. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
3. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
4. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
5. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
6. A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma.
Yin Y; Mao Q; Chen S; Li N; Li X; Li Y
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):455-61. PubMed ID: 26416037
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
9. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
10. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
11. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
12. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake.
Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA
Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584
[TBL] [Abstract][Full Text] [Related]
14. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
15. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
Verburg FA; Verkooijen RB; Stokkel MP; van Isselt JW
Nuklearmedizin; 2009; 48(4):138-42; quiz N19-20. PubMed ID: 19384451
[TBL] [Abstract][Full Text] [Related]
16. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
17. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
[TBL] [Abstract][Full Text] [Related]
18. Decreased uptake after fractionated ablative doses of iodine-131.
Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912
[TBL] [Abstract][Full Text] [Related]
19. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
20. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
Hodgson DC; Brierley JD; Tsang RW; Panzarella T
Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
